K4 Elite
K4 Elite
Growth Hormone Secretagogue
Returns: 14-day returns on un-opened, untampered items in original condition. Return shipping is paid by the buyer. Full policy →
Tesamorelin + Ipamorelin pairs two growth-hormone secretagogues that act on different receptors. Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH) — the body's own signal telling the pituitary to release growth hormone. Ipamorelin is a selective agonist at the ghrelin receptor (GHS-R1a), a separate pathway that also drives GH release. Because the two act through distinct receptors, the published literature examines them as complementary rather than redundant tools.
Growth hormone release from the pituitary is governed by at least two upstream inputs: the GHRH receptor and the ghrelin (GHS-R1a) receptor. Studies of combined GHRH-analog and GHRP administration report that engaging both simultaneously produces a larger GH response than either input alone, an effect described in the endocrine literature as synergistic rather than simply additive [1][3]. The classic demonstration of this used GHRH together with a GH-releasing peptide and measured the resulting GH output against each agent given separately [1].
Tesamorelin is a 44-amino-acid GHRH analog carrying a trans-3-hexenoyl group at the N-terminus. That modification is studied for slowing enzymatic degradation and extending the circulating half-life relative to native GHRH. It binds the pituitary GHRH receptor, a class B G-protein-coupled receptor on somatotroph cells, and is characterised as stimulating the body's own pulsatile GH secretion rather than supplying growth hormone directly. Among GHRH analogs it carries the most substantial clinical trial record, including randomized placebo-controlled studies measuring visceral adipose tissue and hepatic fat by imaging [2].
Ipamorelin is a pentapeptide GH secretagogue. Its defining feature in the literature is selectivity: the original characterisation reported that it releases GH without the measurable rises in ACTH, cortisol or prolactin seen with earlier GH-releasing peptides such as GHRP-6 and GHRP-2 [4]. That clean pharmacological profile is the usual reason it appears in combination research — it adds a second GH-release input without the confounding endocrine signals that make earlier GHRPs harder to interpret.
Because both peptides are co-lyophilized in one vial, they are present in a fixed 1:1 mass ratio and cannot be varied independently. That is convenient for study designs holding the ratio constant, but a design calling for different relative amounts of each compound needs the separate single-compound vials.
Most combination data comes from acute endocrine challenge studies measuring GH output over hours, not from long-term controlled trials of the two compounds given together. Tesamorelin's clinical record is substantial but was generated as monotherapy in a specific population; Ipamorelin has not completed comparable large-scale trials. The synergy described above is a pituitary signalling observation, and published reviews are explicit that combined long-term safety and efficacy in humans is not established [3]. This material is supplied strictly for in-vitro laboratory research.
View COA — Tesamorelin + Ipamorelin GH Stack →
Format. This is a single blended vial containing 20mg total — Tesamorelin 10mg and Ipamorelin 10mg co-lyophilized together. Reconstituting the vial yields one solution carrying both compounds in a fixed 1:1 mass ratio, so any volume drawn contains both in that same proportion. Researchers needing to vary the ratio independently should use the separate single-compound vials instead.
Reconstitution. The blend is a lyophilized powder, reconstituted with bacteriostatic water. Direct the stream against the glass wall rather than onto the powder cake, and swirl gently until dissolved — do not shake, as mechanical agitation can denature peptides. Our reconstitution calculator converts vial mass and diluent volume into concentration and U-100 syringe units.
Storage. Lyophilized vials are typically stored at −20 °C and protected from light. Once reconstituted, peptide solutions are generally refrigerated at 2–8 °C and are less stable than the dry powder. Repeated freeze-thaw cycles are a recognised cause of degradation; aliquoting before freezing avoids them.
Handling. Standard laboratory practice applies: appropriate PPE, aseptic technique when reconstituting, and disposal in line with your institution's procedures. For in-vitro laboratory research only — not for human or veterinary use.